This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice?

Lawrence K. Gottlieb, MD, MPP; Susanne Salem-Schatz, ScD

Arch Intern Med. 1994;154(17):1945-1953.

Abstract
Background
Several recent randomized clinical trials of anticoagulation in atrial fibrillation have demonstrated significant reduction in stroke rates with a small incidence of bleeding complications. The objective of this study was to determine whether the recommendations resulting from these trials have been implemented into routine practice, and if the anticoagulation control, therapeutic efficacy, and low complication rates achieved in the trials have been matched in community practice.

Methods
We analyzed the anticoagulation practices and outcomes obtained for patients in atrial fibrillation at a large staff model health maintenance organization (HMO). We reviewed the medical records of all patients in atrial fibrillation as of April 1990. We compared demographic characteristics and clinical risk factors between HMO patients and those in the clinical trials. We also compared anticoagulation monitoring, adequacy of anticoagulation control, and clinical outcomes at the HMO with those achieved in the clinical trials.

Results
Of 238 HMO patients in atrial fibrillation, 198 were without contraindications and therefore eligible for anticoagulation. Of these, 168 were offered anticoagulation (84.8%) and 156 were receiving anticoagulation therapy (78.8% of those eligible). The HMO patients had a greater prevalence of comorbidities than those in the clinical trials. The routine monitoring interval at the HMO was estimated at between 36.3 and 40.9 days (compared with 21 to 28 days reported in the clinical trials). The prothrombin time ratios at the HMO were in the target range on 50% of days compared with 68% of days in the clinical trials. The annual stroke and major bleeding rates in the HMO patients (1.3% and 0.6%, respectively) were not significantly different from the rates in the clinical trials (1.3% and 1.1%, respectively). The annual minor bleeding rate of 13.6% at the HMO was greater than the 7.8% to 8.4% rates in the two trials with better anticoagulation control (Boston Area Anticoagulation Trial for Atrial Fibrillation and Stroke Prevention in Atrial Fibrillation Study) but was not significantly different than the rates of 12.7% and 13.7% of the two trials with poorer anticoagulation control (Canadian Atrial Fibrillation Anticoagulation Study and Stroke Prevention in Nonrheumatic Atrial Fibrillation Study).

Conclusions
Anticoagulation practices in this community setting appear to be good in that a large majority of patients were receiving anticoagulation therapy, and there were few major adverse outcomes. However, this study illustrates two common problems in attempting to apply the results of randomized clinical trials to routine practice: (1) differences between community patient populations and those on which the conclusions of clinical trials are based, and (2) less successful application of therapeutic interventions in settings other than that of a controlled clinical trial. The greater prevalence of comorbidities in the HMO patient population appears to convey a greater overall risk of thromboembolism and bleeding complications than in the clinical trials. In addition, the suboptimal anticoagulation control achieved at the HMO may increase the risks and decrease the potential benefits compared with those achieved in the clinical trials. Thus, the efficacy demonstrated in the clinical trials of anticoagulation in atrial fibrillation may not be directly translated into effectiveness in practice.

(Arch Intern Med. 1994;154:1945-1953)

Author Affiliations
From the Harvard Community Health Plan, Brookline, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin
Whitlock et al.
Circulation 2009;120:1927-1932.
FULL TEXT  

Oropharyngeal Cleansing With 0.2% Chlorhexidine for Prevention of Nosocomial Pneumonia in Critically Ill Patients: An Open-Label Randomized Trial With 0.01% Potassium Permanganate as Control
Panchabhai et al.
Chest 2009;135:1150-1156.
ABSTRACT | FULL TEXT  

The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation
Perera et al.
Age Ageing 2009;38:156-162.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

A comparative study of anticoagulant control in patients on long-term warfarin using home and hospital monitoring of the international normalised ratio
Bradbury et al.
Arch. Dis. Child. 2008;93:303-306.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation
Nutescu
Am J Health Syst Pharm 2007;64:2281-2291.
FULL TEXT  

Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines
Glazer et al.
Arch Intern Med 2007;167:246-252.
ABSTRACT | FULL TEXT  

Antithrombotic treatment in atrial fibrillation
Kalra et al.
Heart 2007;93:39-44.
FULL TEXT  

Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression
van Walraven et al.
Chest 2006;129:1155-1166.
ABSTRACT | FULL TEXT  

Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Birman-Deych et al.
Stroke 2006;37:1070-1074.
ABSTRACT | FULL TEXT  

Aged Garlic Extract May Be Safe for Patients on Warfarin Therapy
Macan et al.
J. Nutr. 2006;136:793S-795S.
ABSTRACT | FULL TEXT  

Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission
Lim et al.
Int J Qual Health Care 2005;17:255-258.
ABSTRACT | FULL TEXT  

In defence of current treatment options: where are we now?
Voller
Eur Heart J Suppl 2005;7:E4-E9.
FULL TEXT  

Maximizing current treatment options: exploring psychological barriers to change
Murphy
Eur Heart J Suppl 2005;7:E10-E14.
FULL TEXT  

Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation
Miller et al.
Eur Heart J Suppl 2005;7:C41-C54.
ABSTRACT | FULL TEXT  

Anticoagulation in atrial fibrillation and flutter
Scholten et al.
Europace 2005;7:492-499.
ABSTRACT | FULL TEXT  

Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden--a retrospective study of incidence and quality in a registered population
Nilsson et al.
Fam Pract 2004;21:612-616.
ABSTRACT | FULL TEXT  

The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Ansell et al.
Chest 2004;126:204S-233S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Singer et al.
Chest 2004;126:429S-456S.
ABSTRACT | FULL TEXT  

Elimination of the Left Atrial Appendage To Prevent Stroke or Embolism?: Anatomic, Physiologic, and Pathophysiologic Considerations
Stollberger et al.
Chest 2003;124:2356-2362.
ABSTRACT | FULL TEXT  

Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?
Go et al.
JAMA 2003;290:2685-2692.
ABSTRACT | FULL TEXT  

Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial
Wilson et al.
CMAJ 2003;169:293-298.
ABSTRACT | FULL TEXT  

Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation
Johnston et al.
Arch Intern Med 2003;163:1705-1710.
ABSTRACT | FULL TEXT  

Research evidence and the individual patient
Schattner and Fletcher
QJM 2003;96:1-5.
FULL TEXT  

Left atrial appendectomy and maze
Bonanomi et al.
J Am Coll Cardiol 2003;41:170-170.
FULL TEXT  

Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis
van Walraven et al.
JAMA 2002;288:2441-2448.
ABSTRACT | FULL TEXT  

Medication Decisions--Right and Wrong
Stuart and Briesacher
Med Care Res Rev 2002;59:123-145.
ABSTRACT  

Prothrombotic markers in atrial fibrillation: what is new?
Al-Saady and Sopher
Eur Heart J 2001;22:1635-1639.
 

Keynote address
Fieschi and Falcou
Neurology 2001;57:S82-86.
ABSTRACT | FULL TEXT  

Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice?
Evans and Kalra
Arch Intern Med 2001;161:1443-1447.
ABSTRACT | FULL TEXT  

Managing Oral Anticoagulant Therapy
Ansell et al.
Chest 2001;119 :22S-38S.
FULL TEXT  

Warfarin for Stroke Prevention Still Underused in Atrial Fibrillation : Patterns of Omission
Cohen et al.
Stroke 2000;31:1217-1222.
ABSTRACT | FULL TEXT  

Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
Kalra et al.
BMJ 2000;320:1236-1239.
ABSTRACT | FULL TEXT  

Why Do Patients With Atrial Fibrillation Not Receive Warfarin?
Bungard et al.
Arch Intern Med 2000;160:41-46.
ABSTRACT | FULL TEXT  

Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
Ansell et al.
ASH Education Book 2000;2000:266-284.
ABSTRACT | FULL TEXT  

Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Go et al.
ANN INTERN MED 1999;131:927-934.
ABSTRACT | FULL TEXT  

Left atrial appendage: structure, function, and role in thromboembolism
Al-Saady et al.
Heart 1999;82:547-554.
ABSTRACT | FULL TEXT  

Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand?
Deplanque et al.
Heart 1999;82:563-569.
ABSTRACT | FULL TEXT  

Use of antithrombotic measures for stroke prevention in atrial fibrillation
Perez et al.
Heart 1999;82:570-574.
ABSTRACT | FULL TEXT  

Risk Assessment and Anticoagulation for Primary Stroke Prevention in Atrial Fibrillation
Kalra et al.
Stroke 1999;30:1218-1222.
ABSTRACT | FULL TEXT  

Frequency of Major Complications of Aspirin, Warfarin, and Intravenous Heparin for Secondary Stroke Prevention: A Population-Based Study
Petty et al.
ANN INTERN MED 1999;130:14-22.
ABSTRACT | FULL TEXT  

Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring
Ezekowitz et al.
J CARDIOVASC PHARMACOL THER 1999;4:3-8.
ABSTRACT  

Recent National Patterns of Warfarin Use in Atrial Fibrillation
Stafford and Singer
Circulation 1998;97:1231-1233.
ABSTRACT | FULL TEXT  

Atrial Fibrillation and Stroke Prevention With Warfarin in the Long-term Care Setting
Gurwitz et al.
Arch Intern Med 1997;157:978-984.
ABSTRACT  

Anticoagulant Therapy in Patients Aged 80 Years or More With Atrial Fibrillation: More Caution Is Needed
Ackermann
Arch Fam Med 1997;6:105-110.
ABSTRACT  

Thromboembolism Prophylaxis in Chronic Atrial Fibrillation: Practice Patterns in Community and Tertiary-Care Hospitals
Munschauer et al.
Stroke 1997;28:72-76.
ABSTRACT | FULL TEXT  

National Patterns of Warfarin Use in Atrial Fibrillation
Stafford and Singer
Arch Intern Med 1996;156:2537-2541.
ABSTRACT  

Bleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation
The Stroke Prevention in Atrial Fibrillation Inves
Arch Intern Med 1996;156:409-416.
ABSTRACT  

Thoracoscopic Obliteration of the Left Atrial Appendage: Potential for Stroke Reduction?
Odell et al.
Ann. Thorac. Surg. 1996;61:565-569.
ABSTRACT | FULL TEXT  

Appendage Obliteration to Reduce Stroke in Cardiac Surgical Patients With Atrial Fibrillation
Blackshear and Odell
Ann. Thorac. Surg. 1996;61:755-759.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation
Gage et al.
JAMA 1995;274:1839-1845.
ABSTRACT  

Long-term Patient Self-management of Oral Anticoagulation
Ansell et al.
Arch Intern Med 1995;155:2185-2189.
ABSTRACT